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Abstract 
 
Acyclic nucleoside phosphonates (ANPs) are nowadays one of the key drugs in the 
treatment of DNA virus and retrovirus infections. In this work, we report the 
synthesis and antiviral evaluation of phosphonoamidate and diamidates prodrugs 
of C5-pyrimidine acyclic nucleosides derivatives functionalized with but-2-enyl- 
chain. In the phosphonoamidate series, the most active compound 15, showed 
sub-micromolar activity against varicella zoster virus (VZV) (EC50 =0.09-0.5 µM) 
and µM activity against human cytomegalovirus (HCMV) and herpes simplex virus 
(HSV). Separation of single diastereoisomers for compound 14, showed that 14b 
had better anti-herpesvirus activity and no cytotoxicity compared to the 
diastereoisomeric mixture 14. Very interestingly, phosphonodiamidate 21 
showed anti-herpesvirus activity with excellent activity against wild type and 
thymidine kinase-deficient (TK-) VZV strains (EC50 = 0.47 and 0.2 µM, 
respectively) and HCMV (EC50 = 3.5-7.2 µM) without any cytotoxicity (CC50 >100). 
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1. Introduction 
 Acyclic nucleoside phosphonates ȋANPsȌ, nucleotide analogues with a stable P−C 
bond, are the cornerstone of antiviral therapy (De Clercq and Holy, 2005; De 
Clercq et al., 1987; Pertusati et al., 2012). Three ANP analogues; cidofovir (1, CDV, 
Vistide)(De Clercq et al., 1987) adefovir dipivoxil (2, bis-POM PMEA, 
Hepsera)(Clercq et al., 1986), tenofovir  disoproxil (3, TDF, Viread)(Balzarini et 
al., 1993), were the first ANPs approved for the treatment of severe viral infections 
(Figure 1). More recently, Tenofovir alafenamide (formerly GS-7340), a 
phosphoroamidate prodrug of Tenofovir, was developed by Gilead Sciences to 
treat HIV infection and chronic hepatitis B (Callebaut et al., 2015). In November 
2015, the FDA approved its use in the form of tenofovir alafenamide fumarate (4, 
TAF) for HIV therapy (http://www.gilead.com/news/press-
releases/2015/11/us-food-and-drug-administration-approves-gileads-single-
tablet-regimen-genvoya-elvitegravir-cobicistat-emtricitabine-and-tenofovir-
alafenamide-for-treatment-of-hiv1-infection). 
 
Figure 1. ANPs in the market (1-4) and the novel ANPs reported by Agrofoglio (5-6). 
 
The activities of ANPs are based on the intracellular phosphorylation by two 
salvage pathway kinases (nucleoside monophosphate [NMP] and nucleoside 
diphosphate [NDP] kinases) to their diphosphates (ANP-PPs). ANP-PPs mimic the 
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natural nucleoside triphosphates and are the active form capable of inhibiting the 
viral DNA polymerases.(De Clercq, 2007; Pertusati et al., 2012)  
Since the structure of the ANPs side chain strongly influences their antiviral 
selectivity, several series of compounds, modified in their acyclic moiety, have 
been reported. Among them, of particular interest to this project are ANPs 
analogues with a more rigid acyclic chain. The increased rigidity was achieved by 
the introduction of a double bond. This structural feature has been found to be 
important and effective for the antiviral activity of these class of unsaturated ANPs 
(Stella et al., 2014). 
The introduction of an ethenyl unit into the acyclic side chain allows the ANPs to 
better mimic the conformation of the ribose ring. In addition, because a double 
bond has an appreciable electron-withdrawing effect, it maintains an electronic 
contribution similar to the oxygen atom (Hansch and Leo, 1979). This last feature 
assures that the important second dissociation constant of alkenyl-phosphonic 
acids can closely mirror those of the natural phosphate. 
Surprisingly, almost all biologically active ANP are purine derivative. The only 
pyrimidine based ANP in the market is Cidofovir. In order to identify novel and more potent ANPs, Agrofoglio’s group reported the synthesis of several 
pyrimidine ANPs in which the oxygen heteroatom has been replaced with a double 
bond having a trans stereochemistry (Oh et al., 2005), (Amblard et al., 2005a), 
(Amblard et al., 2005b), (Topalis et al., 2011) (McGuigan et al., 2013a).  
Among the different ANPs synthesised, compounds 5 and 6 proved to be efficient 
substrates for the human thymidine monophosphate kinase with their bis-POM 
prodrugs 7 and 8 (Figure 1) showing remarkable antiviral activity. Compound 7 
for example was particularly active against HSV-1 and HSV-2 (EC50 = 3.1 and 6.1 
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µM, respectively) and against TK+ and TK- VZV strains (EC50 = 0.41 and 0.19 µM, 
respectively) but not against HCMV (Topalis et al., 2011).  
To the best of our knowledge, no other prodrug approach other than bis-POM has 
been applied to these interesting pyrimidine scaffolds. In search for more potent 
ANPs, together with a better safety profile, we were interested in study the impact, 
of the phosphonoamidate and phosphonodiamidate prodrugs on the antiviral 
activity of  ANPs 5 and  6 and compare their antiviral activities with those of the 
bis-POM derivatives (Topalis et al., 2011). We were also interested in assessing 
the antiviral activity of the novel compounds against HSV and VZV TK+ and TK- 
strains to prove that our prodrugs are able to bypass the first phosphorylation 
step. 
The phosphoro(no)amidate approach, proved to be extremely successful both on 
nucleoside (Sofosbuvir for Hepatitis C https://www.drugs.com/newdrugs/fda-
approves-sovaldi-chronic-hepatitis-c-3986.html) as well as on acyclic nucleosides 
with the recent approval of the Tenofovir Alafenamide for the treatment of HIV 
infection and chronic hepatitis (http://www.gilead.com/news/press-
releases/2016/11/us-food-and-drug-administration-approves-gileads-vemlidy-
tenofovir-alafenamide-for-the-treatment-of-chronic-hepatitis-b-virus-infection). 
Our group also obtained excellent results using the phosphoroamidate approach 
on adefovir and tenofovir (Pertusati et al., 2014a) as well as on anticancer 
nucleosides (NUC-1031, phase 3 clinical trial for solid tumours and NUC-3373 
among others http://www.nucanabiomed.com/products.html).  
 
2. Materials and methods 
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2.1 Experimental chemistry 
All anhydrous solvents were purchased from Sigma–Aldrich, NMR solvents from 
Cambridge isotope laboratories and reactants from Acros Organics, Sigma Aldrich, 
Alfa Aesar, Fluka, Carbosynth and Molekula. All reagents commercially available 
were used without further purification. Analytical Thin Layer Chromatography 
(TLC): pre-coated aluminium backed plates (60 F254, 0.2 mm thickness, Merck) 
were visualized under 254 nm UV light or using KMnO4. Preparative TLC was 
performed with Analtech blanket 2000, 1000 or 500 m silica gel GF. Flash column 
chromatography was carried out using silica gel supplied by Fisher (60A, 35–70 
mm) or with Biotage Isolera One purification system. Analytical High Performance 
Liquid Chromatography (HPLC) analysis was performed using both Spectra 
System SCM (with X-select-C18, 5 µm, 4.8x150 mm column) and Varian Prostar 
system (LC Workstation-Varian Prostar 335 LC detector). Preparative HPLC was 
performed with Varian Prostar (with pursuit XRs C18 150 x 21.2 mm column). 1H 
NMR (500 MHz), 13C NMR (125 MHz), and 31P NMR (202 MHz) spectra were recorded on a Bruker Avance ͷͲͲ M(z spectrometer at ʹͷ °C. Chemical shifts ȋδȌ 
are quoted in parts per million ȋppmȌ relative to internal MeOD ȋδ=͵.͵Ͷ 1H-NMR, δ=Ͷͻ.ͺ͸ 13C-NMR) and CDCl3 ȋδ=͹.ʹ͸ 1H-NMR, δ=͹͹.͵͸ 13C-NMR) or external 85% 
H3PO4 ȋδ=Ͳ.ͲͲ ͵ͳP-NMR). Coupling constants (J) are given in Hertz. The following 
abbreviations are used in the assignment of NMR signals: s (singlet), d (doublet), 
t (triplet), q (quartet), qn (quintet), m (multiplet), bs (broad singlet), dd (doublet 
of doublet), dt (doublet of triplet). Low resolution mass spectrometry was 
performed on a Bruker Daltonics microTOF-LC system, and as a service by the 
School of Chemistry at Cardiff University. Compounds 5, 6, 11 and 12 were 
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prepared following literature procedures and their 1H, 31P and 13CNMR were in 
accordance with the literature.9  
 
2.1.1 General procedure for preparation of phosphoroamidates prodrugs (13-20) 
phosphonodiamidate (21-23)  
 
In a round bottom flask, under an argon atmosphere, the appropriate diester (11 
or 12) was dissolved in dry acetonitrile (ACN) and treated with an excess of 
TMSBr (5 equivalents). The mixture was then stirred overnight at room 
temperature and then the volatiles evaporated without any contact with air. Then, 
the flask was charged with the appropriate, dry amino acid ester 4- toluene 
sulfonate salt (1 equivalents with respect to the 11 or 12), and the solids dissolved in a mixture of dry triethylamine and dry pyridine ȋͳ:Ͷ v/vȌ and heated to ͷͲ˚C to 
obtain a homogenous solution. To this, it was added a solution of 2,2-
dithiodipyridine (5 equivalents) and triphenylphosphine (5 equivalents) in dry 
pyridine, prepared in a separate flask, under an argon atmosphere. The resulting mixture was stirred at ͷͲ˚C for ͵-4 hours, to reach the complete conversion as 
monitored by TLC (DCM/MeOH 95:5 v/v). After evaporating all the volatiles, the 
residue was treated with a mixture of methanol, water, hexane and toluene 
(1:1:1:1) and transferred into a separatory funnel. The upper layer 
(Hexane/toluene) was separated and the aqueous (MeOH/water) extracted 3 
times with a mixture of toluene/hexane (1:1). The water/methanol layer was 
further extracted with DCM (20 mL x 3). The organics were dried over MgSO4, 
filtered and evaporated. The residue was purified with flash column 
chromatography on silica gel using DCM/MeOH (gradient, usually from 99:1 to 
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95:5 v/v) as eluting mixture and then by preparative TLC (95:5 v/v) or 
preparative HPLC (gradient ACN/water 10:90, 100% ACN in 30 minutes, 100% 
ACN for 5 minutes, then ACN/water 10:90 in 2 minutes). 
 
2.2 Biological assays 
The compounds were evaluated against the following viruses: herpes simplex 
virus type 1 (HSV-1) strain KOS, thymidine kinase-deficient (TK−) HSV-1 KOS 
strain resistant to ACV (ACVr), herpes simplex virus type 2 (HSV-2) strains Lyons 
and G, varicella-zoster virus (VZV) strain Oka, TK− VZV strain Ͳ͹−ͳ, human 
cytomegalovirus (HCMV) strains AD-169 and Davis, vaccinia virus Lederle strain, 
respiratory syncytial virus (RSV) strain Long, vesicular stomatitis virus (VSV), 
Coxsackie B4, Parainfluenza 3, Influenza virus A (subtypes H1N1, H3N2), 
influenza virus B, Reovirus-1, Sindbis, Reovirus-1 and Punta Toro. The antiviral 
assays were based on inhibition of virus-induced cytopathicity or plaque 
formation in human embryonic lung (HEL) fibroblasts, African green monkey cells 
(Vero), human epithelial cells (HeLa) or Madin-Darby canine kidney cells (MDCK). 
Confluent cell cultures in microtiter 96-well plates were inoculated with 100 
CCID50 of virus (1 CCID50 being the virus dose to infect 50% of the cell cultures) or 
with 20 plaque forming units (PFU) (VZV) in the presence of varying 
concentrations of the test compounds. Viral cytopathicity or plaque formation was 
recorded as soon as it reached completion in the control virus-infected cell 
cultures that were not treated with the test compounds. Antiviral activity was 
expressed as the EC50 or compound concentration required to reduce virus-
induced cytopathogenicity or viral plaque formation by 50%. 
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The cytostatic activity measurements were based on the inhibition of cell growth. 
HEL cells were seeded at a rate of 5 x 103 cells/well into 96-well microtiter plates 
and allowed to proliferate for 24 h. Then, medium containing different 
concentrations of the test compounds was added. After 3 days of incubation at 37 
°C, the cell number was determined with a Coulter counter. The cytostatic 
concentration was calculated as the CC50, or the compound concentration required 
to reduce cell proliferation by 50% relative to the number of cells in the untreated 
controls. CC50 values were estimated from graphic plots of the number of cells 
(percentage of control) as a function of the concentration of the test compounds. 
Alternatively, cytotoxicity of the test compounds was expressed as the minimum 
cytotoxic concentration (MCC) or the compound concentration that caused a 
microscopically detectable alteration of cell morphology. 
 
3. Results and discussion 
 
3.1 Chemistry 
Our research began with the synthesis of the alkenyl-functionalized pyrimidine 
methyl phosphonates 11 and 12. The general strategy for the convenient stereo-
controlled synthesis of these trans-alkene acyclic nucleoside phosphonates from 
thymine 9 and bromo-uridine 10 (Scheme 1), was based on olefin cross 
metathesis, developed by Agrofoglio and colleagues. (Topalis et al., 2011) 
Phosphonic acids 5 and 6 (parent nucleosides) were prepared by treatment of 11 
and 12 with an excess of trimethyl bromosilane (TMSBr) followed by aqueous 
workup (Topalis et al., 2011) (Scheme 1).  
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Scheme 1: Synthesis of methyl phosphonates 11 and 12 and the parent phosphonic acids 5a and 6. 
The synthesis of phosphonoamidate prodrugs of these new ANPs was then 
attempted beginning with the phosphonate esters 11 and 12 using the one-pot 
procedure reported by Holy (Jansa et al., 2011) and successfully adapted by us for 
the synthesis of adefovir and tenofovir phosphonoamidate prodrugs (Pertusati et 
al., 2014b). 
Briefly, methylphosphonates 11 and 12 were converted into the correspondent 
silyl esters by treatment with an excess of trimethylsilyl bromide (Jansa et al., 
2011). The silyl derivatives were then treated with an excess of phenol (4 
equivalents) and L-alanine-O-neopentyl ester (4 equivalents), in presence of a 
mixture of triphenylphosphine (5 equivalents) and 2,2-dipyridyl disulphide, 
(Aldrithiol, 5 equivalents). Under this protocol, only traces of the desired 
phosphonoamidate 14 were detected (TLC, Mass spectra, and 31P-NMR of the 
crude mixture) with the phosphonodiamidate 21 being the major product. It is 
clear from these results that the phenol was not nucleophilic enough to compete 
with the amino acid ester for the replacement of the silyl ester. Indeed, when the 
more nucleophilic p-Methoxy phenol was used as aryl alcohol partner in the above 
reaction sequence, the desired ProTide 13 was obtained in 18% yield although 
some diamidate was always isolated. Despite the fact that ProTides bearing para–
Methoxy phenol were successfully applied to glucosamine (Serpi et al., 2012), this 
aryl moiety might be activated too slowly compared to the unsubstituted aryl 
prodrugs (Derudas et al., 2009). To circumvent this potential problem, we 
envisaged that increasing the concentration of phenol would allow us to obtain a 
better yield of the desired ProTide. After several attempts, we found that addition 
of an excess (6 equivalents) of phenol with respect to the L-alanine neopentyl 
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ester tosilate (1 equivalent) was sufficient to obtain a reasonable yield of 
phosphonoamidate (Scheme 2). 
  
Scheme 2: Synthesis of phosphonoamidate and phosphonodiamidate prodrugs from esters 11 and 12; 
Reagents and conditions: a) TMSBr, CH3CN, rt, 8h, Argon atm.; b) Amino acid ester hydrochloride or 
tosylate (1 equiv.), ArOH (6 equiv.), PPh3 (6 equiv.), Aldrithiol-2 (6 equiv.) NEt3/Pyridine (1:4 v/v), 
ͷͲ˚C, Ͷ-8 hours; See table 1 for Ar and R definitions and yields 
However, the phosphonodiamidates were always obtained alongside with the 
desired products (ProTide: diamidate roughly 1:1, at best). This fact was not 
completely unwanted since a one-pot reaction gave us two different prodrugs in a 
fairly reasonable yield. In few cases, with amino acids having bulky esters (L-Ala-
O-hexyl, L-valine-O-pentyl ester, L-isoleucine-Opentyl ester), the yields for both 
products (mono and diamidate) were very low (1-3 %) probably due to steric 
reasons. In some circumstances, it was possible to accomplish the separation by 
column chromatography on silica gel of the two phosphonoamidate 
diastereoisomers. This was achieved with compounds 14 and 20 that were 
isolated as single isomers 14a and 14b and 20a and 20b (Table 1). Compounds 
synthesised by this improved procedure are collected in the table 1: 
 
Cpd. Ar R X Isomers Yield (%) 
5 / / CH3 Parent Nuc 93 
6 / / Br Parent Nuc 12 
13 4-OCH3Ph CH2tBu CH3 Mix 18 
14a Ph CH2tBu   CH3 Single diast. 16 
14b Ph CH2tBu CH3 Single diast. 10 
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15 Naph CH2tBu CH3 Mix 7 
16 5,6,7,8-THNaph CH2Ph CH3 Mix 8 
17a Ph CH2Ph Br Mix 4 
17b Ph CH2Ph Br Single isomer. 3 
18 Naph CH2Ph Br Mix 13 
19 Ph CH2tBu Br Single diast. 16 
20 Ph CH2Ph H Mix 5 
20a Ph CH2Ph H Single diast. 3 
20b Ph CH2Ph H Single diast. 2 
21 / CH2tBu CH3 / 25 
22 / CH2tBu Br / 1 
23 / CH2Ph Br / 2 
Table 1 Compounds synthesised in this study and relative yields. 
 
When, 5-Bromo uracil derivative 12 was subjected to the reaction conditions of 
Scheme 2, we were able to isolate a third compound (other than 
phosphonodiamidate, and ProTide). Analysis by mass spectrometry and 1H-NMR 
of this new compound, revealed that the bromine in the nucleobase was replaced 
with a hydrogen. Indeed, uracil derivative 20 was isolated with a 5% overall yield. 
We attributed the formation of this derivative to the presence of 
triphenylphosphine in the reaction medium. Indeed, it has been shown that 
triphenylphosphine is able to debrominate -bromo-carbonyl compounds 
(Borowitz and Grossman, 1962; Hoffmann and Diehr, 1962).  To investigate if this 
was the case, we set up a control experiment consisting in the treatment of a 
solution of 5-Bromo uracil 24 in a 1:4 mixture of triethylamine and pyridine with 
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triphenylphosphine at ͷͲ˚C. )ndeed, we observed after ͵ hours, the formation of 
the corresponding uracil 25 isolated in 50% yield (Scheme 2).   
 
Scheme 2: Control experiment for the reduction of 5-bromo-uracil 24 to uracil 25 under the reaction 
conditions of Scheme 2. 
The use of TMSBr in the synthetic sequence was considered responsible for the 
low yield due to the bromination of the alkenyl chain.  The low stability of these 
brominated derivatives, whose formation was observed by mass spectrometry, 
did not allow their isolation and characterization. The low yield problem was also 
exacerbated in the case of the 5-bromouracil derivatives. With these substrates, a 
further reduction in the yield of the desired prodrugs was due to the action of the 
triphenyl phosphine, which caused the reduction of the C-Br bond in the 
nucleobase, leading to the formation of the uracil derivatives. The overall result 
was a lower yield of the desired compounds.  
 
3.2 Antiviral evaluation 
With our phosphonoamidates 13-20 and bis-amidates 21-23 in hand, we 
proceeded to investigate their biological activities against a variety of DNA 
viruses. In particular, we were interested in assessing if our prodrugs were able 
to perform better than the bis-POM prodrugs 7 and 8 (Agrofoglio and co-workers 
(Topalis et al., 2011), against HSV-1, Kos strain, HSV-2 (G strain), (TK-) HSV-1 (Kos 
acyclovir-resistant strain), VZV wild-type OKA strain, TK- VZV (07/1 strain), 
HCMV strains AD-169 and Davis, vaccinia virus in HEL cell cultures. 
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As expected from their high polar nature and from literature data1, phosphonic 
acids 5 and 6 resulted totally inactive against all viral strains tested in this study, 
probably due to their inability to permeate inside the cell.  
In the phosphonoamidate family (ProTide), all our prodrugs showed good to 
moderate activity against both TK+ and TK- VZV strains in HEL cells except for 
compound 20 (tested both as 1:1 mixture of diastereoisomers and individual 
isomers, Table 2, entries 14, 15, 16) which showed no activity against HSV and 
only a moderate activity against VZV. In this case, the diastereomeric mixture was 
completely inactive, while one of the two single diastereoisomer 20b, was slightly 
more active than the other 20a. 
Compound 15 (the most active in this phosphonoamidate family) proved to have 
an inhibitory activity against the different HSV-1, HSV-2, VZV and HCMV strains 
with activity slightly better that the Bis(POM) prodrug 7 in the case of HSV-2 (EC50 
= 2.9 vs 6.1 µM) and TK- HSV-1 Kos ACVr, (EC50 = 2.6 vs 9.2 µM). 15 was also less 
toxic than 7 and 8 and in contrast to the Bis(POM) prodrugs proved active against 
HCMV. Evaluation of single isomers of 14 showed that the slow eluting isomer 
(HPLC) 14b, was the most active of the two isomers against HSV, VZV and HCMV 
(Entry 5 vs. 6) and also the less cytotoxic one (14b EC50 >100 vs 14a EC50 = 19.08). 
Compound 16 was moderately active against VZV and HSV and inactive against 
HCMV with a cytotoxicity comparable to 7 (Table 2, Entry 7 vs. 15).  
All phosphonoamidate prodrugs having 5-bromouracil as nucleobase were found 
barely active against HSV, except for 16 that had EC50 values comparable to that 
of the BIS(POM) prodrug 7 (Table 2; Entries 7-12). Although 16 inhibited VZV 
replication with EC50 values in the µM range, it completely lost activity against 
HCMV. 
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Compounds 17 to 19 showed anti-HSV and anti-VZV activity like that of the 
corresponding bis-POM prodrug 8 (Table 2, Entries 8-11 vs 16) but in contrast to 
the latter prodrug they also displayed some anti-HCMV activity. No striking anti-
vaccinia virus was observed with any of the prodrugs having 5-bromouracil as 
nucleobase.  In case of compound 17, the 1:1 mixture of diastereoisomers showed 
the same activity as the single isomers 17b. 
Based on our experience (McGuigan et al., 2013b) phosphoro- and 
phosphonodiamidates are usually less active than the corresponding ProTide, 
probably due to a slower processing rates considering that an amino acid ester is 
less easily displaced than an aryl moiety typical of a ProTide. Quite surprisingly, 
in our study one out of three phosphonodiamidates (21) proved active against 
herpesviruses in HEL cell cultures. Compound 21, showed interesting activity 
against HSV-2 G-strain (EC50 = 8.1 µM), HSV-1 TK- (Kos ACVr strain) (EC50 = 3.6 
µM) and slightly less active against HSV-1 KOS strain (EC50 = 13.8 µM), as 
highlighted in Table 2, Entry 1. This compound had also remarkable activity 
against TK+ and TK- VZV strains (EC50 = 0.47 and 0.20 µM, respectively) and 
proved as active as the reference anti-HCMV drug ganciclovir against human CMV. 
However, this compound was found inactive against HEL cell infected with 
Vaccinia virus (Table 2, Entry 1). 
Replacement of the methyl group in compound 21 by a bromine group gave 
compound 22 resulting in detrimental effects for the anti-herpesvirus activity 
(Table 2 Entry 2). As for compound 21, also 22 was found totally inactive against 
Vaccinia virus (Table 2, Entry 2). The diamidate 23 was found totally inactive 
against HSV, HCMV and vaccinia virus (Table 2, Entry 3) showing only a very weak 
activity against VZV strains. Collectively, compound 21 showed better activity 
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than acyclovir against TK- HSV-1 strain (Kos ACVr), but was found less active than 
cidofovir, acyclovir and ganciclovir against wild-type HSV-1 and HSV-2 strains. 
Finally, the diamidate 21 showed the same antiviral activity against TK+ and TK- 
VZV strains than the bis-POM prodrug 7 but lower potency against HSV strains 
(Table 2, Entries 1 vs Entry 15).  Interestingly, its antiviral activity was better than 
that of the Br-POM prodrug 8 against HSV and VZV except for HSV-1 (Table 2, 
Entries 1 vs Entry 16). Importantly, while prodrugs 7 and 8 were unable to inhibit 
HCMV replication at the higher concentration tested (40 µM), the EC50 values for 
the phosphonodiamidate 21 against HCMV were comparable to those found for 
the reference anti-HCMV drug ganciclovir.  Although prodrugs 7 and 8 were 
moderately active against Vaccinia virus, our diamidate 13 was inactive. Finally, 
all our prodrugs were deprived of activity (EC50 > 100 µM) against the different 
RNA viruses tested. 
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Table 2. Antiviral activity of the synthesized compounds in human embryonic lung (HEL) fibroblasts 
Compound EC50a (HEL) (µM) Cytotoxicity (µM) 
 HSV-1  
(Kos) 
HSV-2 
(G) 
HSV-1 TK- 
KOS ACVr 
VZV TK+ 
(Oka) 
VZV TK-  
(07-1) 
HCMV 
(AD-169) 
HCMV 
(Davis) 
Vaccinia 
virus 
MCCb CC50c 
5 >100 >100 >100 >100 >100 >100 >100 >100 100 ND 
6 >50 >50 >50 >100 >100 >100 >100 >50 >100 ND 
7 3.1 6.1 9.2 0.41 0.19 >40 >40 30 ≥ʹͲͲ 35 
8 20 16 19 20 15 >40 >40 33 ≥ʹͲͲ 34 
14a ≥͸͹ ± 47 39 ± 27 25 ± 18 2.13 ± 
0.04 
0.72 ± 0.27 34.2 13.4 >100 ≥ͳͲͲ 15 ± 5 
14b 8.3 ± 0.9 7.2 ± 0.6 5.8 ± 2.5 0.74 ± 
0.32 
0.35 ± 0.33 10.1 ± 3.5 5.6 ± 0.5 >100 >100 > 100 
15 3.8 ± 3.2 2.9 ± 1.6 2.6 ± 2.0 0.50 ± 
0.42 
0.09 ± 0.05 9.1 ± 1.3 5.6 ± 0.5 ≥͹͵ ± 39 ≥ͳͲͲ 40 ± 3 
16 6.2 ± 3.9 4.4 ± 2.8 4.4 ± 3.4 3.4 ± 3.3 0.8 ± 0.7 >100 >100 >100 ≥ͳͲͲ 24 ± 15 
17 47 ± 18 36 ± 3 25 ± 13 12.9 ± 
7.0 
10.2 ± 3.4 76 67 ≥ͳͲͲ >100 37 ± 19 
17b 30 ± 21 36 ± 3 30 ± 21 13.4 ± 
9.3 
9.7 ± 4.5 63 76 ≥͹ͻ ± 30 >100 ≥ͺ͸ ± 20 
18 35 ± 21 34 ± 0 35 ± 21 15.8 ± 
1.8 
10.2 ± 3.4 49 55 >100 >100 70 ± 27 
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ND: not done 
aEffective concentration required to reduce virus cytopathic effect (HSV, vaccinia virus and CMV) or plaque formation (VZV) by 50%. 
minimum cytotoxic concentration that causes a microscopically detectable alteration of cell morphology. cConcentration required to reduce cell growth by 50%. 
Compound 7: [E]-bis(POM)-TbutP – Compound 8: [E]-bis(POM)-5Br-UbutP 
 
19 33.5 ± 
23.3 
10.5 ± 0.7 27.5 ± 24.7 30.7 ± 
2.4 
9.3 ± 0.5 45 50 >50 >100 68 ± 27 
20 >100 >100 >100 >100 100 >100 >100 >100 >100 ND 
20a >100 >100 >100 72 40 >100 >100 >100 100 ND 
20b >100 >100 >100 39 26 45 41 >100 100 ND 
21 13.8 ± 
8.8 
8.1 ± 3.4 3.6 ± 2.6 0.47 ± 
0.16 
0.20 ± 0.06 7.2 ± 0.5 3.5 ± 0.8 >100 >100 > 100 ± 0 
22 >100 >100 >100 >100 81.8 >100 >100 >100 >100 ND 
23 >100 >100 >100 68 42 >100 >100 >100 >100 ND 
Brivudin 0.072 ± 
0.012 
250 >250 0.012 ± 
0.010 
50.9 ± 16.5 ND ND 19 >300 >300 
Cidofovir 1.81 ± 
0.27 
1.75 ± 0.36 1.81 ± 0.27 ND ND 1.26 ± 0.02 0.76 ± 0 17 ≥͵ͲͲ >300 
Acyclovir 0.42 ± 
0.03 
0.23 ± 0.02 146 2.9 ± 2.1 96.7 ± 5.8 ND ND >250 >440 >440 
Ganciclovir 0.047 ± 
0.023 
0.026 ± 
0.006 
4 ND ND 14.2 ± 2.7 7.3 ± 2.9 >100 >350 >350 
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4. Conclusions 
 
In conclusion, we have successfully synthesised a series of phosphonoamidate and 
diamidates prodrugs of C5-pyrimidine acyclic nucleosides derivatives 
functionalized with but-2-enyl- chain. We were able to demonstrate that the 
phosphonoamidate approach applied to compound 5 and 6 was capable of turning 
these inactive parent nucleosides to active antiviral agents. 
In the phosphonoamidate series, the most active compound 15, showed sub-
micromolar activity against VZV (EC50 = 0.09-0.5 µM) and µM activity against 
HCMV and HSV. Importantly, its activity against both wild type and TK- HSV and 
VZV strains make it a good candidate for the therapy of acyclovir-resistant viruses 
due to mutations in the viral thymidine kinase gene.  In general, our 
phosphonoamidates have a comparable, and in some cases, better antiviral 
activity with respect to the bis-POM derivatives. Very interestingly, our prodrugs 
were able to inhibit HCMV whereas the bis-POM derivatives 7 and 8 were inactive.  
Other analogues of these structural motifs with more complex amino acid moieties 
are under investigation in our laboratory. 
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Figure 1. ANPs in the market (1-4) and the novel ANPs reported by Agrofoglio (5-6). 
 
Scheme 1: Synthesis of methyl phosphonates 11 and 12 and the parent phosphonic 
acids 5a and 6. 
 
Scheme 2: Synthesis of phosphonoamidate and phosphonodiamidate prodrugs from 
esters 11 and 12; Reagents and conditions: a) TMSBr, CH3CN, rt, 8h, Argon atm.; b) 
Amino acid ester hydrochloride or tosylate (1 equiv.), ArOH (6 equiv.), PPh3 (6 
equiv.), Aldrithiol-2 (6 equiv.) NEt3/Pyridine ;ϭ:ϰ v/vͿ, ϱϬ˚C, ϰ-8 hours; See table 1 for 
Ar and R definitions and yields 
 
Scheme 3: Control experiment for the reduction of 5-bromo-uracil 24 to uracil 25 
under the reaction conditions of Scheme 2. 
 
 
 
 
 
Supporting Information 
 
 
Phosphonate Prodrugs of C5-Substituted 
Pyrimidine Acyclic Nucleosides for Antiviral 
Therapy 
 
Fabrizio Pertusati,* ‡ Sara Serafini, ‡ Najmiyah Albadry, ‡ Robert Snoeck,§ and 
Graciela Andrei§ 
  24 
‡School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Redwood 
building, CF10 3NB, Cardiff, Wales, United Kingdom 
§Rega Institute for Medical Research, Department of Microbiology and 
Immunology, KU Leuven, Leuven, Belgium 
 
Author E-mail address: pertusatif@cardiff.ac.uk 
Corresponding Author Footnote: Tel.: +44(0)2920874551. 
 
Contents: 
 
General procedure and data for target compounds                      S2-S11 
 
General procedure for the synthesis of phosphoamidates 13-20 and 
phosphonodiamidates 21-23. 
In a round bottom flask, under an argon atmosphere, the desired diester (11 or 12) was 
dissolved in dry acetonitrile (ACN) and treated with an excess of TMSBr (5 equivalents). 
The mixture was then stirred overnight at room temperature and then the volatiles 
evaporated without any contact with air. Then the flask was charged with the appropriate, 
dry amino acid ester p-toluene sulfonate salt (1 equivalents with respect to the 11 or 12), 
and the solids dissolved in a mixture of dry triethylamine and dry pyridine (1:4 v/v) and heated to ͷͲ˚C to obtain a homogenous solution. To this, it was added a solution of ʹ,ʹ-
dithiodipyridine (5 equivalents) and triphenylphosphine (5 equivalents) in dry pyridine, 
prepared in a separate flask, under an argon atmosphere. The resulting mixture was stirred at ͷͲ˚C for ͵-4 hours, to reach the complete conversion as monitored by TLC 
(DCM/MeOH 95:5 v/v). After evaporating all the volatiles, the residue was treated with a 
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mixture of MeOH, water, hexane and toluene (1:1:1:1) and transferred into a separatory 
funnel. The upper layer (hexane/toluene) was separated and the aqueous (MeOH/water) 
extracted 3 times with a mixture of toluene/hexane (1:1). The water/methanol layer was 
further extract with DCM (20 mL x 3). The organics were dried over MgSO4, filtered and 
evaporated. The residue was purified with flash column chromatography on silica gel 
using DCM/MeOH (gradient, usually from 99:1 to 95:5 v/v) as eluiting mixture and then 
by preparative TLC (95:5 v/v) and/or preparative HPLC (gradient ACN/water 10:90, 
100% ACN in 30 minutes). 
Compounds 13, 15, 16, 17a and 18 were obtained as diastereomeric mixtures. Where 
possible, the characteristic parameters of the signals of the two isomers are described 
separately. 
 
(2S)-neopentyl-2-(((4-methoxyphenoxy)((E)-4-(5-methyl-2,4-dioxo-3,4-
dihydropyrimidin-1(2H)-yl)but-2-en-1-yl) phosphoryl)amino)propanoate (13) 
Compound 13 was prepared according to the general procedure from 11 (200 mg 0.632 
mmol, 1 eq.), TMSBr (483 mg, 3.16 mmol, 5 eq.) in dry ACN (10 mL), L-alanine-O-
neopentyl ester tosylate (843 mg, 2.52 mmol, 4 eq.) and pMeO-phenol (312 mg, 2.52 
mmol, 4 eq.) triphenylphosphine (813 mg, 3.79 mmol, 6 eq.) 2-aldrithiol. (356 mg, 3.79 
mmol, 6 eq.). After workup the crude was purified by silica chromatography column using 
a gradient of DCM/MeOH (99:1 to 95:5 v/v) and providing after preparative TLC (95:5 
v/v) 13 (54 mg, 17% yield).1H-NMR (500 MHz, CD3OD) H 7.41(1H, d, J =1.2 Hz, H-6), 7.39 
(1H, d, J =1.2 Hz, H-6), 7.12 (3H, dd, J= 9.0 and 2.1 Hz, H-Ph,), 6.87 (2H, dd, J = 9.0 and 2.1 
Hz H-Ph), 5.82-5.76 (4H, m, NCH2CH= and =CHCH2P), 4.36-4.24 (4H, m, CH2N), 4.03-3.98 
(2H, m, CHCH3), 3.7 (6H, s, OCH3), 3.34-3.33 (4H, m, CH2(CH3)3), 2.87-2.78 (4H, m, CH2P), 
1.87 (6H, s, CH3), 1.34 (3H, d, J = 7.2 Hz, CHCH3), 1.26 (3H, d, J = 7.3Hz, CHCH3), 0.96 (18H, 
s, C(CH3)3).  13C-NMR (125 MHz, CD3OD) δC: 175.49 (d, 3JPC = 4.9 Hz, COO), 175.13 (d, 3JPC = 
3.7 Hz, COO), 158.23 (C-4), 166.88 (C-ipso PhOCH3), 150.45 (C-2), 150.38 (d 2JCP = 9.1 Hz, 
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C-ipso PhOP), 142.66 (CH-6), 142.64 (CH-6), 130.91 (d, 2JPC = 14.8 Hz, =CH-CH2P), 130.90 
(d, 2JPC =14.86 Hz, =CHCH2P), 122.92 (d, 3JPC = 4.8 Hz, CH-Ph), 122.75 (d, 3JPC = 3.7 Hz, CH-
Ph), 115.66(CH-Ph), 115.64 (CH-Ph), 111.45 (C-5), 111.42 (C-5), 50.12 (CHCH3), 50.27 
(CHCH3), 56.11 (CH2N), 56.08 (CH2N), 32.56 (d, 1JPC = 129.3 Hz, CH2P), 32.46 (d, 1JPC = 129.5 
Hz, CH2P), 30.90 (C(CH3)3),  26.74 (C(CH3)3), 26.73 (C(CH3)3), 21.45 (d, 3JPC = 5.6 Hz, 
CHCH3), 20.85 (d, 3JPC = 4.9 Hz, CHCH3), 12.29 (CH3). 12.28 (CH3) 31P-NMR (202 MHz, 
CD3OD) P 28.76, 29.35 ppm. HPLC:  254 nm, F = 1mL/min, tR =15.14 min. (gradient from 
ACN/water 10:90 to 100% ACN in 30 minutes. MS(ESI+) m/z=508.2 [M + H+]. 
 
(2S)-neopentyl2-((((E)-4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-
but-2-en-1-yl)(phenoxy)phosphoryl)amino) propanoate (14a and 14b) and 
(2S,2'S)-dineopentyl-2,2'-((((E)-4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-
1(2H)-yl)- but-2-en-1-yl)phosphoryl)bis(azanediyl))dipropanoate (21)  
Compound 14a, 14b and 21 were prepared according to the general procedure from 11 
(87 mg, 0.275 mmol, 1 eq.), TMSBr (210.6 mg, 1.38 mmol, 5 eq.) in dry ACN (10 mL), L-
alanine-O-neopentyl ester tosylate (91.1 mg, 0.275 mmol, 1 eq.) and phenol (432.9 mg, 
1.65 mmol, 6 eq.) triphenylphosphine (363.6 mg, 1.65 mmol, 6 eq.) 2-aldrithiol. (155.3 
mg, 1.65 mmol, 6 eq.). After workup, the crude was purified by silica chromatography 
column using a gradient of DCM/MeOH (99:1 to 95:5 v/v) and providing preparative TLC 
(95:5 v/v) 14a (21.6 mg, 16% yield). Rf (DCM/MeOH 95:5 v/v) = 0.32. 1H-NMR (500 MHz, 
CD3OD) H 7.41 (1H, d, J = 1.1 Hz, H-6), 7.38-7.34 (2H, m, CH-Ph), 7.21-7.18 (3H, m, CH-
Ph), 5.83-5.79 (2H, m, NCH2CH= and =CHCH2P), 4.36 (2H, t, J =4.8 Hz, CH2N), 4.05-3.99 
(1H, m, CHCH3), 3.87, 3.77 (2H, AB, JAB = 10.5 Hz, CH2C(CH3)3), 2.87 (2H, ddd, J = 6.4 and 
4.6 Hz, 2JPH=20.5 Hz, CH2P), 1.87 (3H, d, J =1.2 Hz, CH3), 1.26 (3H, d, J =7.3 Hz, CHCH3), 0.96 
(9H, s, C(CH3)3) ppm.  31C-NMR (125 MHz, CDCl3) C 174.05 ((d, 3JPC = 4.9 Hz, COO), 163.9 
(C-4), 150.67 (C-2), 150.38 (d 2JCP = 9.1 Hz, C-ipso Ph), 139.74 (CH-6), 129.77 (CH-Ph), 
129.47 (d, 2JPC=10.7 Hz, =CHCH2P), 129.21 (d, 3JPC=14.7 Hz, NCH2CH=), 124.64 (CH-Ph), 
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120.68 (d, 3JPC=4.5 Hz, CH-Ph), 111.00 (C-5), 74.71 (CH2C(CH3)3), 49.73 (CHCH3 ), 49.49 
(CH2N), 32.44 (d, 1JPC = 127.2 Hz, CH2P), 29.69 (C(CH3)3), 26.32  (C(CH3)3), 21.53 (d 3JPC = 
6.3 Hz, CHCH3), 10.87 (CH3) ppm. 31P-NMR (202 MHz, CD3OD) P 29.23 ppm. HPLC: = 
280 nm, F = 1 mL/min, tR =16.06 min. (gradient from ACN/water 10:90 to 100% ACN in 30 
minutes. MS(ESI+) m/z= 500.2 [M + Na+] (100%). 
  
Further elution with (DCM/MeOH 95:5 v/v) and preparative TLC (95:5 v/v) followed by 
preparative HPLC provided 14b (13.2 mg, 10% yield). Rf (DCM/MeOH 95:5 v/v) = 0.29. 
1H-NMR (500 MHz, CD3OD) H 7.37 (1H, d, J=1.1 Hz, H-6), 7.35-7.32 (2H, m, CH-Ph), 7.22-
7.17 (3H, m, CH-Ph), 5.79-5.76 (2H, m, NCH2CH= and =CHCH2P), 4.35 (2H, m, CH2N), 3.91, 
3.82 (2H, AB, JAB = 10.5 Hz, CH2C(CH3)3), 3.67-3.60 (1H, m, CHCH3), 2.86-2.80 (2H, m, 
CH2P), 1.87 (3H, s, CH3), 1.38 (3H, d, J = 7.2 Hz, CHCH3), 0.99 (9H, s, C(CH3)3) ppm..31C-NMR 
(125 MHz, CDCl3) C 173.79 (d, 3JPC =4.9 Hz, COO), 164.01 (C-4), 150.72 (C-2), 150.43 (d, 
2JCP = 7.84 Hz, C-ipso Ph), 139.66 (CH-6), 129.77 (CH-Ph), 129.24 (d, 2JP C= 14.7 Hz, 
=CHCH2P), 125.16 (d, 2JPC = 11.0 Hz, NCH2CH=), 124.86 (CH-Ph), 120.47 (d, 3JPC = 4.9 Hz, 
CH-Ph), 111.05 (C-5), 74.78 (CH2C(CH3)), 49.62 (CHCH3), 49.23 (CH2N), 32.79 (d, 1JPC = 
130.8 Hz, CH2P), 29.70 (C(CH3)3), 29.36 (C(CH3)3), 21.79 (d, 3JPC = 2.5 Hz, CHCH3), 12.30 
(CH3) ppm. 31P-NMR (202 MHz, CDCl3) P 28.51 ppm. HPLC: = 280 nm, F = 1 mL/min, tR 
= 16.14 min (gradient from ACN/water 10:90 to 100% ACN in 30 minutes). MS(ESI+) 
m/z= 500.2 [M + Na+] (100%).  
  
Further elution with a gradient DCM/MeOH (95:5 to 93:7 v/v) and preparative TLC (95:5 
v/v) afforded 21 (34.9 mg, yield=25%). Rf (DCM/MeOH 95:5 v/v) = 0.20. 1H-NMR (500 
MHz, CD3OD) H 7.30 (1H, d, J = 1.2 Hz, H-6), 5.69-5.58 (2H, m, NCH2CH= and =CHCH2P), 
4.38-4.28 (2H, m, CH2N), 4.06-4.96 (2H, m, CHCH3), 3.78, 3.76 (2H, AB, JAB = 10.5 Hz, 
CH2C(CH3)3), 3.68, 3.65 (2H, AB, JAB = 10.5 Hz, CH2C(CH3)3), 2.71-2.58 (2H, m, CH2P), 1.78 
(3H, d, J = 1.2 Hz, CH3), 1.42 (3H, d, J = 7.0 Hz, CHCH3), 1.40 (3H, d, J = 7.0 Hz, CHCH3), 0.86 
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(9H, s, C(CH3)3), 0.85 (9H, s, C(CH3)3) ppm. 31C-NMR (125 MHz, CD3OD) C 174.54 (d, 3JPC = 
4.9 Hz, COO), 174.43 (d, J = 4.0 Hz, COO), 165.51 (C-4), 151.47 (C-2), 141.31 (CH-6), 128.67 
(d, 2JPC= 13.0 Hz, =CHCH2P), 125.29 (d, 3JPC = 10.2 Hz, NCH2CH=), 110.03 (C-5), 74.03 
(CH2C(CH3)3), 73.96 (CH2C(CH3)3), 48.85 (CH2N), 48.80 (CHCH3), 48.50 (CHCH3), 32.93 (d, 
1JPC = 110.2 Hz, CH2P), 30.90 (C(CH3)3), 25.40 (C(CH3)3), 20.13 (d, 3JPC = 6.3 Hz, CHCH3), 
19.92 (d, 3JPC = 5.6 Hz, CHCH3), 10.94 (CH3) ppm. 31P-NMR (202 MHz, CD3OD) P27.35 ppm. 
HPLC: = 280 nm, F = 1 mL/min, tR = 17.59 min (gradient from ACN/water 10:90 to 100% 
ACN in 30 minutes). MS(ESI+) m/z = 543.3 [M + H+] (50%), m/z=565.3 [M + Na+] (100%).  
 
(2S)-neopentyl-2-((((E)-4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-
but-2-en-1-yl)(naphthalen-1-yloxy)phosphoryl) amino)propanoate (15) 
Compound 15 was prepared according to general procedure from 11 (216 mg, 0.752 
mmol, 1 eq.) TMSBr (575.99 mg, 0.49 mL, 3.76 mmol, 5 eq.) (in dry ACN (10 mL), 1-
naphthol (650.9 mg, 4.51 mmol, 6 eq.), L-alanine-O-neopentyl ester tosylate (249.39 mg, 
0.752 mmol, 1 eq.), triphenylphosphine (262.3 mg, 4.51 mmol, 6 eq.) and 2-aldrithiol 
(994.6 mg, 4.51 mmol, 6 eq.). After workup, the crude was purified by silica 
chromatography column using a gradient of DCM/MeOH (99:1 to 95:5 v/v) and providing 
after preparative TLC (95:5 v/v) 15 (26 mg, 7% yield). Rf (DCM/MeOH 95:5 v/v) = 
0.39.1H-NMR (500 MHz, CD3OD) H 8.02 (2H, d, J =6.02 Hz, CH-Naph), 7.77 (1H, d, J =6.02 
Hz, CH-Naph), 7.76 (1H, d, J = 6.0 Hz, CH-Naph), 7.58 (2H, dd, J= 8.0, J=1.0 Hz,  CH-Naph), 
7.43-7.21 (8H, m, CH-Naph), 7.21 (2H, m, H-6), 5.80-5.65 (4H, m, NCH2CH= and =CHCH2P), 
4.23-4.17 (4H, m, CH2N), 4.02-3.92 (2H, m, CHCH3), 3.72, 3.58 (2H, AB, JAB = 10.5 Hz, 
CH2C(CH3)), 3.60, 3.56 (2H, AB, JAB = 10.5 Hz, CH2C(CH3), 2.94-2.82 (4H, m, CH2P), 1.65 
(3H, d, J = 1.2 Hz, CH3), 1.18 (3H, d, J = 6.8 Hz, CHCH3), 1.10 (3H, d, J =7.2 Hz, CHCH3), 0.81 
(9H, s, C(CH3)3), 0.76 (9H, s, C(CH3)3) ppm.  31C-NMR (125 MHz, CDCl3) C 174.02 (d, J = 4.2 
Hz, COO), 173.57 (d, J = 4.8 Hz, COO),  165.41(C-4), 165.39 (C-4), 151.44 (C-2), 151.35 (C-
2), 146.45 (d, 2JPC = 9.3 Hz, C-ipso Naph), 146.31 (d, 2JPC = 9.3 Hz, C-ipso Naph), 141.12 (CH-
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6), 141.08 (CH-6), 134.91 (C-Naph), 129.68 (d, 2JPC = 14.9 Hz, =CHCH2P), 129.68 (d, 2JPC 
=14.9 Hz, =CHCH2P), 127.46, 127.45, (CH-Naph), 126.72 (d, 3JPC = 5.6 Hz, C-Naph), 126.59 
(d, 3JPC = 5.6 Hz C-Naph), 126.36, 126.05 (CH-Naph), 125.13 (d, 3JPC = 8.4 Hz, CH-Naph), 
124.34 (d, J = 8.3 Hz, CH-Naph), 123.91 (d, 3JPC = 11.0 Hz, NCH2CH=), 123.69 (d, 3JPC =11.0 
Hz, NCH2CH=), 121.44 (CH-Naph), 121.31 (CH-Naph), 115.34 (d, 3JPC = 3.7 Hz, CH-Naph), 
115.11 (d, 3JPC = 4.2 Hz, CH-Naph), 110.07 (C-5), 73.88 (CH2C(CH3)3), 73.92 (CH2C(CH3)3), 
49.61 (CHCH3), 49.44 (CHCH3), 48.78 (CH2N), 48.67 (CH2N), 32.22 (d, 1JPC = 129.6 Hz, 
CH2P), 31.97 (d, 1JPC = 129.6 Hz, CH2P), 30.92 (C(CH3)3), 31.97 (C(CH3)3), 25.34 (C(CH3)3), 
25.39 (C(CH3)3), 19.94 (d, 3JPC =5.1 Hz, CHCH3), 19.27 (d, 3JPC=5.1 Hz, CHCH3), 10.84 (CH3) 
ppm. 31P-NMR (202 MHz, CDCl3) P 29.51, 28.86, ppm. HPLC: = 280 nm, F = 1mL/min, tR 
= 18.23 min (gradient from ACN/water 10:90 to 100% ACN in 30 minutes,). MS(ESI+) m/z 
= 550.2 [M + Na+] (100%).  
 
(2S)-benzyl-2-((((E)-4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-but-
2-en-1-yl)((5,6,7,8-tetrahydronaphthalen-1-yl)oxy)phosphoryl) 
amino)propanoate (16) 
Compound 16 was prepared according to the general procedure, from 11 (116.30 mg, 
0.45 mmol, 1 eq.), TMSBr (342.16 mg, 0.30 mL, 2.23 mmol, 5 eq.), dry ACN (5 mL) 
aldrithiol-2 (598.9 mg, 2.72 mmol, 6 eq.) 5,6,7,8-tetrahydro-1-napthol (402.9 mg, 2.72 
mmol, 6 eq.) L-alanine-O-benzyl ester tosylate (159.2 mg, 0.453 mmol, 1 eq.) and 
triphenylphosphine (713.1 mg, 2.72 mmol, 6 eq.). Then the mixture has been stirred for 
5 hours at ͷͲ˚C. After workup, the crude was purified by silica chromatography 
column using a gradient of DCM/MeOH (99:1 to 95:5 v/v) and providing after 
preparative TLC (95:5 v/v) followed by preparative HPLC 16 (21 mg, 8% yield). Rf 
(DCM/MeOH 95:5 v/v) = 0.25. 1H-NMR (500 MHz, CDCl3) H 8.89 (1H, bs, NH), 7.33-7.22 
(5H, m, CH-Ar), 7.10 (1H, d, J = 8.7 Hz, CH-TetrahydroNaph), 6.91 (1H, d, J = 1.0 Hz, H-6), 
6.90 (1H, J = 8.7 Hz, CH-TetrahydroNaph), 6.76 (1H, J = 8.1 Hz, CH-TetrahydroNaph), 5.73-
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5.42 (2H, m, NCH2CH= and =CHCH2P), 5.05–4.99 (2H, m, CH2Ph), 4.18 (2H, t, J = 5.3 Hz, 
CH2N), 4.02-3.94 (1H, m, CHCH3), 2.69-2.64 (4H, m, CH2-TetrahydroNaph and CH2P), 2.56-
2.52 (2H, m, CH2-TetrahydroNaph), 1.80 (3H, s, CH3), 1.67-1.66 (4H, m, CH2-
TetrahydroNaph), 1.25 (3H, d, J = 7.9 Hz, CHCH3). 31C-NMR (125 MHz, CDCl3) C 173.62 (d, 
J = 5.9 Hz, COO), 164.14 (C-4), 150.80 (C-2), 148.75 (d, 2JPC= 8.8 Hz, C-ipso 
TetrahydroNaphOP), 139.59 (CH-6), 139.49 (C-ipso CH2Ph), 135.23 (C-TetrahydroNaph), 
129.16 (d, 2JPC= 13.7 Hz, =CHCH2P), 128.65, 128.54, 128.22 (CH-Ar), 128.10 (d, 2JPC= 4.8 
Hz, C-TetrahydroNaph), 125.92, 125.51 (CH-Ar), 125.26, (d, 2JPC= 10.97 Hz, NCH2CH=) 
116.83 (d, 3JPC = 3.3 Hz, CH-TetrahydroNaph), 110.02 (C-5), 67.25 (CH2Ph), 49.69 (d, 2JPC = 
4.3 Hz, CHCH3), 49.20 (CH2N), 32.91 (d, 1JPC = 129.6 Hz, CH2P), 29.51 (CH2-
TetrahydroNaph), 23.72 (CH2-TetrahydroNaph), 22.22 (2 x CH2-TetrahydroNaph), 21.53 
(d, 3JPC = 4 Hz, CHCH3), 12.25 (CH3) ppm. 31P-NMR (202 MHz, CDCl3) P 29.70, 29.19, ppm. 
HPLC: = 280 nm, F = 1 mL/min, tR = 17.90 min (gradient from ACN/water 10:90 to 100% 
ACN in 30 minutes). MS (ESI+) m/z= 574.2 [M + Na+] (100%).  
 
(2S)-benzyl2-((((E)-4-(5-bromo-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-but-2-
en-1-yl)(phenoxy) phosphoryl)amino)propanoate (17a and 17b) and (2S)-benzyl-
2-((((E)-4-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-but-2-en-1-
yl)(phenoxy)phosphoryl)amino)propanoate (20a and 20b)  
Compounds 17a, 17b, 20a and 20b were prepared according to the general procedure, 
from 12 (309.0 mg, 0.811 mmol, 1 eq.) TMSBr (620.6 mg, 4.05 mmol, 0.53 mL, 5 eq.) dry 
ACN (10 mL) Aldrithiol-2 (1.07 g, 4.86 mmol, 6 eq.) phenol (457.8 mg, 4.86 mmol, 6 eq.) 
L-alanine-O-benzyl ester tosylate (284.9 mg, 0.811 mmol, 1 eq.) of, triphenylphosphine 
(1.28 g, 4.86 mmol, 6 eq.) After workup, the crude was purified by silica chromatography 
column using a gradient of DCM/MeOH (99:1 to 95:5 v/v) and providing after preparative 
TLC (95:5 v/v) 17a (17 mg, 4% yield). Rf (DCM/MeOH 95:5 v/v) = 0.30. 1H-NMR (500 
MHz, CD3OD) H 7.97 (1H, s, H-6), 7.96 (1H, s, H-6), 7.39-7.29 (14H, m, CH-Ar), 7.20-7.15 
  31 
(6H, m, CH-Ph), 5.84-5.66 (4H, m, NCH2CH= and =CHCH2P), 5.16, 5.12 (2H, d, AB JAB = 10.5 
Hz, CH2Ph), 5.092 (2H, s, CH2Ph), 4.37-4.29 (4H, m, CH2N), 4.08-4.00 (2H, m, CHCH3), 2.87-
2.75 (4H, m, CH2P), 1.30 (3H, d, J =7.1 Hz, CHCH3), 1.24 (3H, d, J = 6.9 Hz, CHCH3) ppm. 31C-
NMR (125 MHz, CD3OD) C 173.78 (d, 3JPC  = 4.8 Hz, COO), 173.40 (d, 3JPC = 4.8 Hz, COO), 
160.71 (C-4), 160.69 (C-4), 150.73 (C-2), 150.63 (C-2), 150.48 (d, 2JPC = 9.2 Hz, C-ipso Ph), 
150.31 (d, 2JPC = 9.2 Hz, C-ipso Ph), 144.85 (C-6), 135.89 (C-ipso CH2Ph), 135.86 (C-ipso 
CH2Ph), 129.35 (CH-Ar), 129.02 (CH-Ar), 129.10 (d, 2JPC=13.5 Hz, =CHCH2P), 128.98 (d, 
3JPC=14.2 Hz, =CHCH2P), 128.25 (CH-Ar), 128.22 (CH-Ar), 128.05 (CH-Ar), 128.03 (CH-Ar), 
128.01 (CH-Ar), 127.97 (CH-Ar), 124.73 (CH-Ar), 124.66 (CH-Ar), 124.50 (d, 3JPC= 9.04 Hz, 
NCH2CH=), 124.40 (d, 3JPC= 10.04 Hz, NCH2CH=),120.72 (d, 3JPC=4.3 Hz, CH-Ph), 120.50 (d, 
3JPC = 4.5 Hz, CH-Ph), 95.35 (C-5), 66.60 (CH2Ph), 66.54 (CH2Ph), 49.58 (CHCH3), 49.49 
(CHCH3), 49.40 (CH2N), 49.28 (CH2N), 31.99 (d, 1JPC = 128 Hz, CH2P), 31.85 (d, 1JPC = 128 
Hz, CH2P), 19.71 (d, 3JPC = 5.4 Hz, CHCH3), 19.10 (d, 3JPC= 5.6 Hz, CHCH3) ppm. 31P-NMR (202 
MHz, CD3OD) P 29.13 (0.67P), 28.36 (0.33P). HPLC: = 280 nm, F = 1mL/min, tR = 16.26 
min (gradient from ACN/water 10:90 to 100% ACN in 30 minutes). MS (ESI+) m/z= 584.0 
[M + Na+] (100%), 586.0 [M+Na+] (98%). 
 
Further elution with (DCM/MeOH 95:5 v/v) provided after preparative TLC (95:5 v/v) 
followed by preparative HPLC 17b (11.0 mg, 3% yield). Rf (DCM/MeOH 95:5 v/v) = 0.29. 
1H-NMR (500 MHz, CD3OD) H 7.97 (1H, s, H-6), 7.38-7.30 (7H, m, CH-Ar), 7.21-7.15 (3H, 
m, CHPh), 5.81-5.69 (2H, m, NCH2CH= and =CHCH2P), 5.09 (2H, s, CH2Ph), 4.38-4.31 (2H, 
m, CH2N), 4.06-4.00 (1H, m, CHCH3), 2.86-2.75 (2H, m, CH2P), 1.30 (3H, d, J = 6.9 Hz, 
CHCH3) ppm.  31C-NMR (125 MHz, CD3OD) C 175.44 (d, 3JPC = 3.7 Hz, COO), 162.82 (C-4), 
152.72 (C-2), 152.34 (d, 2JPC = 9.3 Hz, C-ipso Ph), 146.81 (CH-6), 137.72 (C-ipso CH2Ph), 
131.31 (CH-Ar), 131.01 (d, 2JPC = 14.5 Hz, =CHCH2P), 130.14 (CH-Ar), 129.93 (CH-Ar), 
129.91 (CH-Ar), 126.55 (CH-Ar), 126.34 (d, 3JPC= 11.03 Hz, NCH2CH=), 122.41 (d, 3JPC = 4.8 
Hz, CH-Ph), 97.35 (C-5), 68.51 (CH2Ph), 51.42 (CHCH3), 51.24 (CH2N), 33.73 (d, JPC = 129.0 
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Hz, CH2P), 21.61 (d, 3JPC = 5.7 Hz, CHCH3) ppm. 31P-NMR (202 MHz, CD3OD) P 28.49 ppm. 
HPLC: = 280 nm, F = 1 mL/min, tR = 16.42 min (gradient from ACN/water 10:90 to 100% 
ACN in 30 minutes). MS (ESI+) m/z= 584.0 [M + Na+] (100%), 586.0 [M+ Na+] (98%).  
 
Further elution with (DCM/MeOH 94:6 v/v) provided after preparative TLC (95:5 v/v) 
followed by preparative HPLC 20a (10.7 mg, 3% yield). Rf (DCM/MeOH 95:5 v/v) = 0.25. 
1H-NMR (500 MHz, CD3OD) H 7.52 (1H, d, J = 7.9 Hz, H-6), 7.39-7.32 (7H, m, CH-Ar), 7.21-
7.16 (3H, m, CH-Ph), 5.82-5.68 (2H, m, NCH2CH= and =CHCH2P), 5.66 (1H, d, J =7.9 Hz, H-
5), 5.04, 5.01 (2H, AB JAB = 8 Hz, CH2Ph), 4.32 (2H, t, J = 4.5 Hz, CH2N), 4.04 (1H, m, CHCH3), 
2.81 (2H, m, CH2P), 1.23 (3H, d, J=7.3Hz, CHCH3) ppm. 31C-NMR (125 MHz, CD3OD) C 
173.86 (d, 3JPC=4.0 Hz, COO), 165.34 (C-4), 151.33 (C-2), 150.32 (d, 2JPC= 9.5 Hz, C-ipso Ph), 
145.44 (CH-6), 135.91 (C-ipso CH2Ph), 129.31 (CH-Ar), 129.22 (d, 2JPC = 14.1 Hz, =CHCH2P), 
128.25 (CH-Ar), 128.02 (CH-Ar), 124.66 (CH-Ar), 124.25 (d, 3JPC=11.2 Hz, NCH2CH=), 
120.67 (d, 3JPC =4.4 Hz CH-Ph), 101.14 (C-5), 66.60 (CH2Ph), 49.48 (CHCH3), 49.08 (d, JPC = 
2.6 Hz, CH2N), 33.51 (d, 1JPC = 129.5 Hz, CH2P), 19.07 (d, 3JPC = 5.5 Hz, CHCH3) ppm. 31P-NMR 
(202 MHz, CD3OD) δP 29.58 ppm. HPLC: = 280 nm, F = 1 mL/min, tR = 14.32 minutes 
(gradient from ACN/water 10:90 to 100% ACN in 30 minutes). MS(ESI+) m/z = 506.1 [M 
+ Na+] (100%).  
 
Further elution with (DCM/MeOH 94:6 v/v) provided after preparative TLC (95:5 v/v) 
followed by preparative HPLC 20b (5.9 mg, 2% yield). Rf (DCM/MeOH 95:5 v/v) = 0.22. 
1H-NMR (500 MHz, CD3OD) δH7.41 (1H, d, J = 7.9 Hz, H-6), 7.23-7.18 (7H, m, CH-Ar), 7.08-
7.05 (3H, m, CH-Ph), 5.65-5.61 (2H, m, NCH2CH= and =CHCH2P), 5.54 (1H, d, J = 7.9 Hz, H-
5), 5.09 (2H, s, CH2Ph), 4.23-4.21 (2H, m, CH2N), 3.94-3.89 (1H, m, CHCH3), 2.71-2.65 (2H, 
m, CH2P), 1.18 (3H, d, J=6.9 Hz, CHCH3) ppm. 31C-NMR (125 MHz, CD3OD) δC 173.86 (d, 3JPC  
= 4.5 Hz, COO), 165.34 (C-4), 151.33 (C-2), 150.32 (d, 2JPC =10 Hz, C-ipso Ph), 145.70 (CH-
6), 135.91 (C-ipso CH2Ph), 129.66 (CH-Ar), 129.58 (d, 2JPC =14.8 Hz, =CHCH2P), 128.52 (CH-
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Ar), 128.29 (CH-Ar), 124.87 (CH-Ar), 124.40 (d, 3JPC = 10.1 Hz, NCH2CH=), 120.74 (d, 3JPC = 
4.6 Hz, CH-Ph), 101.43 (C-5), 66.79 (CH2Ph), 49.68 (CHCH3), 49.28 (d, 4JPC=2.1 Hz, CH2N), 
32.14 (d, 1JPC= 129.5 Hz, CH2P), 19.97 (d, 3JPC = 5.2 Hz, CHCH3) ppm. 31P-NMR (202 MHz, 
CD3OD) δP 28.40 ppm. HPLC: = 280 nm, F = 1 mL/min, tR = 14.51 min (gradient from 
ACN/water 10:90 to 100% ACN in 30 minutes). MS (ESI+) m/z= 506.1 [M + Na+] (100%).  
 
 (2S)-benzyl-2-((((E)-4-(5-bromo-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-but-
2-en-1-yl)(naphthalen-1-yloxy)phosphoryl)amino)propanoate (18) and 
(ʹS,ʹ'SȌ- dibenzyl ʹ,ʹ'-ȋȋȋȋEȌ-Ͷ-ȋͷ-bromo-ʹ,Ͷ-dioxo-͵,Ͷ-dihydropyrimidin-ͳȋʹHȌ-
ylȌ-but-ʹ-en-ͳ-ylȌ phosphorylȌbisȋazanediylȌȌdipropanoate ȋʹ͵Ȍ  
Compounds 18 and 23 was prepared according to general procedure from 11 (240.0 mg, 
0.629 mmol, 1 eq.) of TMSBr (481.9 mg, 3.15 mmol, 0.42 mL, 5 eq.) dry ACN (10 mL) 
aldrithiol-2 (0.832 g, 3.78 mmol, 6 eq.) naphthol (544.7 mg, 3.78 mmol, 6 eq.) L-alanine-
O-benzyl ester tosylate (663.9 mg, 1.89 mmol, 3 eq.), triphenylphosphine (0.990 g, 3.78 
mmol, 6 eq.) After workup, the crude was purified by silica chromatography column using 
a gradient of DCM/MeOH (99:1 to 95:5 v/v) and preparative TLC (95:5 v/v) providing 18 
(50 mg, 13% yield). Rf (DCM/MeOH 95:5 v/v) = 0.29 – 0.26.  1H-NMR (500 MHz, CD3OD) δH 8.12 (2H, m, CH-Naph), 7.89-7.87 (4H, m, CH-Naph), 7.67 (2H, d, J = 8.8 Hz, CH-Naph), 
7.55-7.50 (6H, m, CH-Naph), 7.37-7.26 (12H, m, H-6 and CH-Ph), 5.85-5.74 (2H, m, 
NCH2CH=) 5.74-5.70 (2H, m, =CHCH2P), 5.14-4.95 (4H, m, CH2Ph), 4.29 (4H, bs, CH2N), 
4.01-4.06 (2H, m, CHCH3), 2.95-2.91 (4H, m, CH2P), 1.27 (3H, d, J=7.1 Hz, CHCH3), 1.19 (3H, 
d, J = 7.1 Hz, CHCH3) ppm. 31C-NMR (125 MHz, CD3OD) δC 173.30 (d, 3JPC = 3.8 Hz, COO), 
160.66 (C-4), 150.58 (C-2), 146.42 (d, 2JPC= 9.6 Hz, C-ipso Naph), 144.74 (CH-6), 135.78 (C-
ipso CH2Ph), 134.89 (C-Naph), 129.21 (d, 2JPC = 14.4 Hz, =CHCH2P), 128.13, 127.89, 127.50 
(CH-Ar) 126.59 (d, 3JPC = 4.9Hz, C-Naph), 126.35 (d, 3JPC = 10.8 Hz, NCH2CH=), 125.15, 
124.37, 124.35, 121.30 (CH-Ar), 115.21 (d, 3JPC = 4.3Hz, CH-Naph), 95.39 (C-5), 66.47 
(CH2Ph), 49.51 (CHCH3), 49.27 (d, 4JPC= 1.6 Hz, CH2N), 32.15 (d, 1JPC=129.2 Hz, CH2P), 31.95 
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(d, 1JPC = 129.2 Hz, CH2P), 19.62 (d, 3JPC = 6.8 Hz, CHCH3) 19.44 (d, 3JPC = 6.8 Hz, CHCH3) 
ppm. 31P-NMR (202 MHz, CD3OD) δP 26.84, 26.46 ppm. HPLC: = 280 nm, F = 1mL/min, tR 
= 16.50 (gradient from ACN/water 10:90 to 100% ACN in 30 minutes). MS (ESI+) m/z= 
636.1 [M + Na+](100%), 638.1 [M + Na+](98%). 
 
Further elution with (DCM/MeOH 95:5 v/v) provided after preparative TLC (95:5 v/v) 
23 (7.0 mg, 2% yield). Rf (DCM/MeOH 95:5 v/v) = 0.16. 1H-NMR (500 MHz, CD3OD) δH 
7.84 (1H, s, H-6), 7.27-7.23 (10H, m, CH-Ph), 5.66-5.52 (2H, m, NCH2CH= and =CHCH2P), 
4.19-4.16 (2H, m, CH2N), 3.90-3.83 (2H, m, CHCH3), 2.53-2.39 (2H, m, CH2P), 1.27 (3H, d, J 
= 7.2 Hz, CHCH3), 1.19 (3H, d, J = 7.2 Hz, CHCH3) ppm. 31C-NMR (125 MHz, CD3OD) δC 
174.23 (d, 3JPC = 4.7 Hz, COO), 174.17 (d, 3JPC = 4.3 Hz, COO), 160.78 (C-4), 150.75 (C-2), 
144.86 (CH-6), 135.96 (C-ipso CH2Ph), 135.93 (C-ipso CH2Ph), 128.24 (CH-Ph), 128.11 (d, 
2JPC = 14.2 Hz, =CHCH2P), 128.07 (CH-Ph), 128.00, (CH-Ph), 126.03 (d, 3JPC = 10.4 Hz, 
=CHCH2N), 95.40 (C-5), 66.63 (CH2Ph), 66.60 (CH2Ph), 49.12 (d, 4JPC = 2.1 Hz, CH2N), 48.91 
(CHCH3), 48.51 (CHCH3), 33.88 (d, 1JPC = 110.7 Hz, CH2P), 19.73 (d, 3JPC = 5.9 Hz, CHCH3), 
19.66 (d, 3JPC  = 6.0 Hz, CHCH3) ppm. 31P-NMR (202 MHz, CD3OD) δP23.95 ppm. HPLC: = 
280 nm, F = 1 mL/min, tR = 16.53 minutes (gradient from ACN/water 10:90 to 100% 
ACN in 30 minutes). MS (ESI+) m/z= 671.7 [M + Na+] (98 %), 669.1 [M + Na+] (100%). 
 (2S)-neopentyl-2-((((E)-4-(5-bromo-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-
but-2-en-1-yl)(phenoxy)phosphoryl)amino) propanoate (19) and (2S,2'S)-
dineopentyl-2,2'-((((E)-4-(5-bromo-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-
yl)but-2-en-1-yl)phosphoryl)bis(azanediyl))dipropanoate (22)  
Compound 19 and 22 were prepared according to the general procedure from 12 (316.0 
mg, 0.892 mmol, 1 eq.) TMSBr (682.8 mg, 4.46 mmol, 0.59 mL, 5 eq.) dry ACN (10 mL) 
aldrithiol-2 (1.18 g, 5.35 mmol, 6 eq.) phenol (503.7 mg, 5.35 mmol, 6 eq.) of, L-alanine-
O-neopentyl ester tosylate (886.9.9 mg, 2.68 mmol, 3 eq.) and triphenylphosphine (1.40 
g, 5.35 mmol, 6 eq.). After workup, the crude was purified by silica chromatography 
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column using a gradient of DCM/MeOH (99:1 to 95:5 v/v) and providing after preparative 
TLC (95:5 v/v) followed by preparative HPLC 19 (77 mg, 16% yield). Rf (DCM/MeOH 95:5 
v/v) = 0.20. 1H-NMR (500 MHz, CDCl3) δH 7.53 (1H, s, H-6), 7.23-7.20 (2H, m, CH-Ph), 7.13-
7.11 (2H, m, CH-Ph), 7.06-7.02 (1H, m, CHPh), 5.84-5.76 (1H, m, =CHCH2P), 5.68-5.61 (1H, 
m, NCH2CH=), 4.27 (2H, s, CH2N), 4.11-4.09 (1H, m, NH), 4.04-3.97 (1H, m, CHCH3), 3.76, 
3.65 (2H, AB, JAB = 10.5 Hz, CH2C(CH3)3), 2.78-2.75 (2H, m, CH2P), 1.26 (3H, d, J =7.4 Hz, 
CHCH3), 0.84 (9 H, s, C(CH3)3) ppm. 31C-NMR (125 MHz, CDCl3) δC 173.93 (d, 3JPC = 5.2 Hz, 
COO), 159.76 (C-4), 150.42 (d, 2JPC = 9.2 Hz, C-ipso Ph), 150.34 (C-2), 143.27 (CH-6), 129.75 
(CH-Ph), 128.58 (d, 2JPC = 14.2 Hz, =CHCH2P), 126.16 (d, 3JPC =10.3 Hz, NHCH2CH=), 124.82 
(CH-Ph), 120.47 (d, 3JPC = 4.3 Hz, CH-Ph), 96.65 (C-5), 74.75 (CH2C(CH3)3), 49.68 (CH2N), 
49.66 (CHCH3), 32.60 (d, 1JPC = 128.5 Hz, CH2P), 30.90 (C(CH3)3), 26.34 (C(CH3)3), 21.60 (d, 
3JPC = 4 Hz, CHCH3) ppm. 31P-NMR (202 MHz, CDCl3Ȍ δP 26.25 ppm. HPLC: = 280 nm F = 1 
mL/min, tR = 17.24 min (gradient from ACN/water 10:90 to 100% ACN in 30 minutes). 
MS (ESI+) m/z= 566.1 [M + Na+] (98%), 564.1 [M + Na+], (100%) 
 
Further elution with (DCM/MeOH 95:5 v/v) provided after preparative TLC (95:5 v/v) 
22 (5.3 mg, 1% yield). Rf (DCM/MeOH 95:5 v/v) = 0.16. 1H-NMR (500 MHz, CDCl3) δH 7.53 
(1H, s, H-6), 5.66-5.59 (1H, m, NCH2CH=), 5.25- 5.11(1H, m, =CHCH2P), 4.29-4.27 (2H, m, 
CH2N), 4.04-3.99 (2H, m, CHCH3), 3.82, 3.66 (2H, AB, JAB = 10.4 Hz, CH2C(CH3)3), 3.81, 3.71 
(2H, AB, JAB = 10.4 Hz, CH2C(CH3)3), 3.15-3.07 (2H, m, NH), 2.57 (2H, dd, J=7.6, 2JPH = 19.6 
Hz, CH2P), 1.37 (3H, d, J = 7.2 Hz, CHCH3), 1.34 (3H, d, J = 7.2 Hz, CHCH3), 0.87 (9H, s, 
C(CH3)3), 0.86 (9H, s, C(CH3)3) ppm. 31C-NMR (125 MHz, CDCl3) δC 174.84 (d, 3JPC = 5.1 Hz, 
COO), 174.75 (d, 3JPC = 5.1 Hz, COO), 159.26 (C-4), 150.01 (C-2), 143.25 (CH-6), 128.11 (d, 
2JPC = 9.9 Hz, =CHCH2P), 127.58 (d, 3JPC = 13.8Hz, NCH2CH=), 96.73 (C-5), 74.82 (CH2(CH3)3), 
74.76 (CH2(CH3)3), 49.99 (CH2N), 49.00 (CHCH3), 48.55 (CHCH3), 34.26 (d, 1JPC = 109.1 Hz, 
CH2P), 31.46 (C(CH3)3), 26.34 (C(CH3)3), 21.71 (d, 3JPC = 4.8 Hz, CHCH3), 21.51 (d, 3JPC = 4.9 
Hz, CHCH3) ppm. 31P-NMR (202 MHz, CD3OD) δP 23.68 ppm. HPLC: = 280 nm, F = 1 
  36 
mL/min, tR = 18.48 min (gradient from ACN/water 10:90 to 100% ACN in 30 minutes). 
MS (ESI+) m/z= 629.1  [M + Na+] (100%), 631.1 [M + Na+] (98%). 
 
 
 
